Abstract
MANY carcinogens can elicit antibodies when linked to macromolecular carriers1–5. If antibodies against an entire class of carcinogens could be elicited by a non-carcinogenic analogue, and proved capable of neutralising the biological effects of the carcinogens, human immunisation might be of practical value. Mucosal (predominantly IgA) antibodies, capable of facilitating the excretion of an antigen before its absorption into the body, might be particularly useful in this6,7. Here we provide evidence that: an analogue of the polycyclic aromatic hydrocarbon (PAH) carcinogen dim-ethylbenzanthracene (DMBA), substituted with a fluorine moiety to abrogate carcinogenicity, can induce antibodies which bind a variety of PAH carcinogens; that these antibodies can protect tissue culture cells against one of the prominent in vitro biological effects of such carcinogens—toxicity; and that gastrointestinal mucosal immunisation against PAH carcinogens is feasible, and possibly represents a means of achieving in vivo protection by enhancing carcinogen excretion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
